- Home
- MIST
as 03-25-2025 12:35pm EST
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
| Founded: | 2003 | Country: | Canada |
| Employees: | N/A | City: | MONTREAL |
| Market Cap: | 98.1M | IPO Year: | N/A |
| Target Price: | $17.00 | AVG Volume (30 days): | 2.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.67 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.12 - $2.75 | Next Earning Date: | 03-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 1105.43% |
Latest Milestone Pharmaceuticals Inc. News
MIST Breaking Stock News: Dive into MIST Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology
Associated Press Finance
13 days ago
Milestone Pharmaceuticals: Q4 Earnings Snapshot
GlobeNewswire
13 days ago
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update
GlobeNewswire
22 days ago
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
a month ago
Milestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference
MT Newswires
a month ago
Milestone Pharmaceuticals Gets Notice of Allowance for US Patent on Etripamil Nasal Spray
GlobeNewswire
a month ago
Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil
GlobeNewswire
a month ago
Milestone Pharmaceuticals to Host Commercial Launch Plan Investor Event in New York on February 25, 2025
Compare MIST vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MIST Milestone Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.